OMGA Omega Therapeutics Inc

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences.

Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 9:30 a.m. ET

Goldman Sachs 45th Annual Global Healthcare ConferenceDate: Monday, June 10, 2024Time: 10:40 a.m. ET

Live webcasts of the fireside chats will be available on the Investors section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the same website for approximately 90 days.

About Omega TherapeuticsOmega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.

For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn.

Contact:

Eva Stroynowski
617.949.4370
estroynowski@omegatx.com